Should Investors Like Bristol-Myers' Buyout of Celgene?
The pharmaceutical giant’s $74 billion bid for the biotechnology player sent the acquirer’s shares significantly lower, but that’s hardly unusual.
Sunday, January 6, 2019
Should Investors Like Bristol-Myers' Buyout of Celgene?
Should Investors Like Bristol-Myers' Buyout of Celgene?
The pharmaceutical giant’s $74 billion bid for the biotechnology player sent the acquirer’s shares significantly lower, but that’s hardly unusual.
Related Posts:
0 comments:
Post a Comment